OGT CEO Cites 'Exceptional Demand' for Cyto Chips in Decision to Establish US Office | GenomeWeb

Oxford Gene Technology has expanded its effort to serve its North American cytogenetic array customers by establishing an office near New York City and appointing a US-based sales team.

The UK-based clinical genetics company previously served its North American customers from its headquarters outside Oxford, but was moved to establish a direct presence in the US because of "exceptional demand" for its cyto chips, CEO Mike Evans told BioArray News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.